Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer

Surgical Oncology Clinics of North America

Volumn 25, Issue 2, 2016, Pages 311-326

  Li, Daneng ^a   O'Reilly, Eileen M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant therapy; Clinical trials; Neoadjuvant therapy; Pancreas adenocarcinoma

Indexed keywords

CAPECITABINE; CP 870893; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; IMMUNOTHERAPY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; ERLOTINIB HYDROCHLORIDE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 84958213450     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2015.11.010     Document Type: Review

References (55)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Garcea G., Dennison A.R., Pattenden C.J., et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systemic review of the literature. JOP 2008, 9:99-132.
3. Kalser M.H., Ellenber S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
4. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782.
5. Smeenk H.G., van Eijck C.H., Hop W.C., et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation. Long-term results of EORTC trial 40891. Ann Surg 2007, 246:734-740.
6. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001, 358:1576-1585.
7. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
8. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
9. Oettle H., Neuhaus P., Hochhaus A., et al. Adjuvant chemotherapy with gemcitabine and long term outcomes among patients with resected pancreatic cancer. The CONKO-001 randomized trial. JAMA 2013, 310:1473-1481.
10. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019-1026.
11. Berger A.C., Garcia M., Hoffman J.P., et al. Postresection Ca 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008, 26:5918-5922.
12. Neoptolemos J.P., Stocken D.D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
13. Saif M.W., Syrigos K.N., Katirzoglou N.A. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 2009, 18:335-348.
14. Fukutomi A., Uesaka K., Boku N., et al. JASPAC 01: randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 2013, 31. [meeting abstract: 4008].
15. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
16. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.
17. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2007, 25:1960-1966.
18. Sinn M., Liersch T., Gellert K., et al. CONKO-005: adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study. J Clin Oncol 2015, 33. [meeting abstract: 4007].
19. Hammel P., Huguet F., Van Laethem J.L., et al. Comparison of chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol 2013, 31. [meeting abstract: 4003].
20. Weden S., Klemp M., Gladhaug I.P., et al. Long term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011, 128:1120-1128.
21. Abou-Alfa G.K., Champman P.B., Feilchenfeldt J., et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011, 3:321-325.
22. Shaw V.E., Naisbitt D.J., Costello E., et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010, 9:1007-1016.
23. Middleton G.W., Valle J.W., Wadsley J., et al. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol 2013, 31. [meeting abstract: 4004].
24. Jaffee E.M., Hruban R.H., Biedrzycki B., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19:145-156.
25. Lutz E., Yeo C.J., Lillemoe K.D., et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg 2011, 253:328-335.
26. Galili U., LaTemple D.C. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997, 18:281-285.
27. LaTemple D.C., Abrams J.F., Zhang S.Y., et al. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha 1,3 glactosyltransferase. Cancer Res 1999, 59:3417-3423.
28. Hardacre J.M., Mulcahy M.F., Small W., et al. Addition of algenpantucel-L immunotherapy to standard of care adjuvant therapy for pancreatic cancer. J Clin Oncol 2012, 30. [meeting abstract: 4049].
29. Belli C., Cereda S., Anand S., et al. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev 2013, 39:518-524.
30. Cooper A.B., Tzeng C.W., Katz M.H. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol 2013, 14:293-310.
31. Papavasiliou P., Chun Y.S., Hoffman J.P. How to define and manage borderline resectable pancreatic cancer. Surg Clin North Am 2013, 93:663-674.
32. Kelly K.J., Winslow E., Kooby D., et al. Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of "borderline resectable disease"?. J Gastrointest Surg 2013, 17:1209-1217.
33. Halperin D.M., Varadhachary G.R. Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?. Curr Oncol Rep 2014, 16:366.
34. He J., Page A.J., Weiss M., et al. Management of borderline and locally advanced pancreatic cancer: where do we stand?. World J Gastroenterol 2014, 20:2255-2266.
35. Kang C.M., Hwang H.K., Choi S.H., et al. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Surg Oncol 2013, 22:123-131.
36. Ishikawa O., Ohigashi H., Imaoka S., et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?. Arch Surg 1994, 129:1075-1080.
37. Staley C.A., Lee J.E., Cleary K.R., et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996, 171:118-124.
38. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997, 15:928-937.
39. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.
40. Talamonti M.S., Small W., Mulcahy M.F., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006, 13:150-158.
41. Xu C.P., Xue X.J., Liang N., et al. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014, 140:549-559.
42. Heinrich S., Pestalozzi B.C., Schafer M., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:2526-2531.
43. Motoi F., Ishida K., Fujishima F., et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013, 20:3794-3801.
44. Sahora K., Kuehrer I., Eisenhut A., et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011, 149:311-320.
45. Sahora K., Kuehrer I., Schindl M., et al. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 2011, 35:1580-1589.
46. Leone F., Gatti M., Massucco P., et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 2013, 119:277-284.
47. O'Reilly E.M., Perelshteyn A., Jarnagin W.R., et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 2014, 260:142-148.
48. Boone B.A., Steve J., Krasinskas A.M., et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013, 108:236-241.
49. Christians K.K., Tsai S., Mahmoud A., et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?. Oncologist 2014, 19:266-274.
50. Faris J.E., Blaszkowsky L.S., McDermott S., et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013, 18:543-548.
51. Katz M.H., Shi Q., Ahmad S.A., et al. Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101. J Clin Oncol 2015, 33. [meeting abstract: 4008].
52. Katz M.H., Marsh R., Herman J.M., et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013, 20:2787-2795.
53. Tempero M.A., Malafa M.P., Behrman S.W., et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2014, 12:1083-1093.
54. Heinrich S., Pestalozzi B., Lesurtel M., et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011, 11:346.
55. Beatty G.L., Torigian D.A., Chiorean E.G., et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013, 19:6286-6295.